• 2022年6月21-23日
  • 上海新国际博览中心N5馆




COVID-19 病原样抗原(PLA) 疫苗的免疫效力研究
Study on the efficacy of COVID-19 pathogen-like antigen (PLA) vaccine




Baidong Hou
Principle Investigator
Institute of Biophysics, CAS


Baidong Hou is currently a principle investigator in the key laboratory of infection and immunity at the Institute of Biophysics (IBP), Chinese Academy of Sciences. He studied medicine at Peking University and obtained his bachelor’s degree in 1994, and then practiced medicine at Peking Union Medical College (PUMC) Hospital. He completed his M.D. training in critical care medicine with Dr. Dechang Chen at PUMC at 2001. He shifted his interest to basic research and received his postdoctoral training first in Dr. Douglas Vaughan’s lab at Vanderbilt University and then in Dr. Anthony DeFranco’s lab at University of California, San Francisco (UCSF). In 2011, he was recruited by IBP and moved back to China to establish his own lab. His research interest is to understanding the mechanism by which the adaptive immunity, especially B cell antibody response is regulated by innate immune signals in complex conditions such as viral infection and autoimmunity. His lab developed a serial of new tools and methods that allow them to examine antigen-specific B cell responses to a novel virus-like particle antigen that can closely mimics the properties of some viruses. These new tools are helping them to undercover some previously unappreciated functions of B cells that could have profound impact on vaccine design and therapy for autoimmunity.